Glutamate dehydrogenase and alkaline phosphatase as very early predictors of hepatocellular carcinoma recurrence after liver transplantation

Digestion

Volumn 91, Issue 2, 2015, Pages 117-127

  Piras Straub, Katja ^a   Khairzada, Khaleda ^a   Gerken, Guido ^a   Saner, Fuat ^a   Treckmann, Jürgen ^a   Paul, Andreas ^a   Canbay, Ali ^a   Herzer, Kerstin ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

GLDH; HCC; Liver transplantation; NASH; Tumor recurrence

Indexed keywords

ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; BIOLOGICAL MARKER; CYCLOSPORIN A; EVEROLIMUS; GLUTAMATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SORAFENIB; TACROLIMUS; TUMOR MARKER;

ADULT; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CORRELATION ANALYSIS; FEMALE; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; TUMOR VOLUME; BLOOD; CANCER GRADING; CARCINOMA, HEPATOCELLULAR; ENZYMOLOGY; FIBROSIS; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDY; RISK; TUMOR RECURRENCE;

ADULT; AGED; ALKALINE PHOSPHATASE; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; FEMALE; FIBROSIS; GLUTAMATE DEHYDROGENASE; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDIES; RISK; TUMOR MARKERS, BIOLOGICAL;

EID: 84923115946     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000370212     Document Type: Article

References (28)

1. Bruix J, Gores GJ, Mazzaferro V: Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut 2014; 63: 844-855.
2. Ravaioli M, Ercolani G, Neri F, Cescon M, Stacchini G, Del Gaudio M, Cucchetti A, Pinna AD: Liver transplantation for hepatic tumors: a systematic review. World J Gastroenterol 2014; 20: 5345-5352.
3. Welker MW, Bechstein WO, Zeuzem S, Trojan J: Recurrent hepatocellular carcinoma after liver transplantation-an emerging clinical challenge. Transpl Int 2013; 26: 109-118.
4. Molmenti EP, Klintmalm GB: Liver transplantation in association with hepatocellular carcinoma: an update of the international tumor registry. Liver Transpl 2002; 8: 736-748.
5. Shirabe K, Toshima T, Kimura K, Yamashita Y, Ikeda T, Ikegami T, Yoshizumi T, Abe K, Aishima S, Maehara Y: New scoring system for prediction of microvascular invasion in patients with hepatocellular carcinoma. Liver Int 2014; 34: 937-941.
6. Kashkoush S, El Moghazy W, Kawahara T, Gala-Lopez B, Toso C, Kneteman NM: Threedimensional tumor volume and serum alphafetoprotein are predictors of hepatocellular carcinoma recurrence after liver transplantation: refined selection criteria. Clin Transplant 2014; 28: 728-736.
7. Xiao GQ, Liu C, Liu DL, Yang JY, Yan LN: Neutrophil-lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation. World J Gastroenterol 2013; 19: 8398-8407.
8. Lee JY, Kim YH, Yi NJ, Kim HS, Lee HS, Lee BK, Kim H, Choi YR, Hong G, Lee KW, Suh KS: Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation. Clin Mol Hepatol 2014; 20: 192-203.
9. Cholongitas E, Mamou C, Rodriguez-Castro KI, Burra P: Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review. Transpl Int 2014; 27: 1039-1049.
10. Lai Q, Lerut JP: Hepatocellular cancer: how to expand safely inclusion criteria for liver transplantation. Curr Opin Organ Transplant 2014; 19: 229-234.
11. Gugenheim J, Bredt LC, Iannelli A, Decaens T, Roudot-Thoraval F, Meyer C, Durand F, Bernard PH, Boillot O, Sulpice L, Calmus Y, Hardwigsen J, Ducerf C, Pageaux GP, Dharancy S, Chazouilleres O, Cherqui D, Duvoux C, Hadni-Bresson S: Recurrence after liver transplantation for hepatocellular carcinoma according to up-to-seven criteria. Hepatogastroenterology 2013; 60: 799-806.
12. Lei JY, Wang WT, Yan LN: 'Metroticket' predictor for assessing liver transplantation to treat hepatocellular carcinoma: a single-center analysis in mainland China. World J Gastroenterol 2013; 19: 8093-8098.
13. Raj A, McCall J, Gane E: Validation of the 'Metroticket' predictor in a cohort of patients transplanted for predominantly HBV-related hepatocellular carcinoma. J Hepatol 2011; 55: 1063-1068.
14. Grat M, Kornasiewicz O, Lewandowski Z, Holowko W, Grat K, Kobryn K, Patkowski W, Zieniewicz K, Krawczyk M: Combination of morphologic criteria and alpha-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence. World J Surg 2014; 38: 2698-2707.
15. Dumitra TC, Dumitra S, Metrakos PP, Barkun JS, Chaudhury P, Deschenes M, Paraskevas S, Hassanain M, Tchervenkov JI: Pretransplantation alpha-fetoprotein slope and milan criteria: strong predictors of hepatocellular carcinoma recurrence after transplantation. Transplantation 2013; 95: 228-233.
16. Aleksandrova K, Boeing H, Nothlings U, Jenab M, Fedirko V, Kaaks R, Lukanova A, Trichopoulou A, Trichopoulos D, Boffetta P, Trepo E, Westhpal S, Duarte-Salles T, Stepien M, Overvad K, Tjonneland A, Halkjaer J, Boutron-Ruault MC, Dossus L, Racine A, Lagiou P, Bamia C, Benetou V, Agnoli C, Palli D, Panico S, Tumino R, Vineis P, Bueno-de-Mesquita B, Peeters PH, Gram IT, Lund E, Weiderpass E, Quiros JR, Agudo A, Sanchez MJ, Gavrila D, Barricarte A, Dorronsoro M, Ohlsson B, Lindkvist B, Johansson A, Sund M, Khaw KT, Wareham N, Travis RC, Riboli E, Pischon T: Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer. Hepatology 2014; 60: 858-871.
17. Bozorgzadeh A, Orloff M, Abt P, Tsoulfas G, Younan D, Kashyap R, Jain A, Mantry P, Maliakkal B, Khorana A, Schwartz S: Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis. Liver Transplant 2007; 13: 807-813.
18. Waki K, Sugawara Y, Tamura S, Mieno MN, Yamashiki N, Kadowaki T, Kokudo N: Outcome of liver transplantation for recipients with hepatitis B and hepatitis C virus coinfection: analysis of the UNOS data. Transplantation 2011; 92: 809-814.
19. Muir AJ: The rapid evolution of treatment strategies for hepatitis C. Am J Gastroenterol 2014; 109: 628-635; quiz 636.
20. Wong RJ, Cheung R, Ahmed A: Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 2014; 59: 2188-2195.
21. Heuer M, Kaiser GM, Kahraman A, Banysch M, Saner FH, Mathe Z, Gerken G, Paul A, Canbay A, Treckmann JW: Liver transplantation in nonalcoholic steatohepatitis is associated with high mortality and post-transplant complications: a single-center experience. Digestion 2012; 86: 107-113.
22. Ertle J, Dechene A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn WK, Canbay A: Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011; 128: 2436-2443.
23. Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A: The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol 2012; 56: 952-964.
24. Castroagudin JF, Molina-Perez E, Ferreiro-Iglesias R, Abdulkader I, Otero-Anton E, Tome S, Varo-Perez E: Late recurrence of hepatocellular carcinoma after liver transplantation: is an active surveillance for recurrence needed? Transplant Proc 2012; 44: 1565-1567.
25. Schnitzbauer AA, Schlitt HJ, Geissler EK: Influence of immunosuppressive drugs on the recurrence of hepatocellular carcinoma after liver transplantation: a gap between basic science and clinical evidence. Transplantation 2011; 91: 1173-1176.
26. Castroagudin JF, Molina-Perez E, Ferreiro-Iglesias R, Varo-Perez E: Strategies of immunosuppression for liver transplant recipients with hepatocellular carcinoma. Transplant Proc 2011; 43: 711-713.
27. Vivarelli M, Dazzi A, Zanello M, Cucchetti A, Cescon M, Ravaioli M, Del Gaudio M, Lauro A, Grazi GL, Pinna AD: Effect of different immunosuppressive schedules on recurrencefree survival after liver transplantation for hepatocellular carcinoma. Transplantation 2010; 89: 227-231.
28. Roayaie K, Roayaie S: Liver transplant for hepatocellular cancer: very small tumors, very large tumors, and waiting time. Clin Liver Dis 2014; 18: 603-612.